Wockhardt
FDA hits Wockhardt again; this time over Illinois plant
04 June 2014
FDA forces Wockhardt to withdraw yet another generic drug from US
17 May 2014
Wockhardt Q3 net down 29% at Rs304 crore
10 February 2014
Wockhardt’s Swiss arm to list on Berne exchange today; shares spurt
19 December 2013
Regulatory curbs pull down Wockhardt Q2 net 69% to Rs138.50 crore
26 October 2013
Wockhardt faces fresh strictures from UK drug regulator
23 October 2013
Wockhardt recalls 5 drugs in UK after regulatory strictures
19 October 2013
Wockhardt gets another slap from UK drug regulator
14 October 2013
Wockhardt gets another blast from US drug regulator FDA
28 September 2013
British drug regulator recalls 16 Wockhardt drugs
11 July 2013
Wockhardt reports consolidated Q4 net profit of Rs334.767 crore
28 May 2013
Wockhardt to launch generic hypertension drug in US
21 August 2012
Wockhardt completes divestment of nutrition business to Danone
26 July 2012
Fortis in talks over control of Wockhardt Hospitals: report
21 May 2012
Cough up dues or face liquidation, HC tells Wockhardt
08 September 2011
Danone to buy Wockhardt's nutrition business for Rs1,576 crore
03 August 2011
Danone in talks to buy Wockhardt's nutrition business: report
26 July 2011
Wockhardt receives tentative US FDA approval for generic version of Patanol ophthalmic solution
01 July 2011
Wockhardt launches three new products in the United States
21 June 2011
Wockhardt receives US FDA approval for generic Alzheimer's drug
25 April 2011
Wockhardt's generic version of Pfizer's Effexor XR capsules gets US FDA approval
19 April 2011
HC stays winding-up plea against Wockhardt
23 March 2011
HC nod for winding up Wockhardt; company to appeal
12 March 2011
Wockhardt launches generic version of ulcer drug `Protonix' in US
21 January 2011
Wockhardt launches prostate drug Flomax in the US
28 April 2010
Wockhardt deal with Abbott falls through as foreign investors cry foul
03 April 2010
Bombay HC rejects plea to block Wockhardt deal with Abbott
18 January 2010
Wockhardt receives US FDA approval for antibacterial Levofloxacin
13 January 2010
Wockhardt gets US FDA approval for Alzheimer's drug Memantine
06 January 2010
Fortis completes deal to pocket 10 Wockhardt hospitals
19 December 2009
Wockhardt settles with lender DBS Bank out of court
30 November 2009
Wockhardt launches anti-hypertension drug Nicardipine injections in the US
18 November 2009
Wockhardt reports Rs54 crore Q3 net loss
31 October 2009
Wockhardt receives US FDA approval for prostrate drug
29 September 2009
Wockhardt is top Indian pharma patentee; bags government award
24 September 2009
Fortis acquires 10 Wockhardt hospitals for Rs909 crore
24 August 2009
Wockhard to sell 10 hospitals to Fortis for around Rs1,200 crore
22 August 2009
Wockhardt completes sale of veterinary business to Vétoquinol
20 August 2009
Wockhardt sells its nutrition businesses to Abbott for $130 million
28 July 2009
Cash-strapped Wockhardt sells veterinary arm to France’s Vetoquinol
29 June 2009
Wockhardt sells German arm to Mova Pharma
18 June 2009
Apollo Hospitals dumps plan to acquire Wockhardt assets
17 June 2009
Wockhardt to hive off animal health care business
07 May 2009
Pfizer brings patent infringement suits against Sun, Lupin, Wockhardt
06 May 2009
Wockhardt settles patent row with Orion Corporation
29 April 2009
Wockhardt reports Rs139 crore net loss in Q4'08
25 April 2009
Wockhardt CMD Khorakiwala quits; Fortis takeover likely
01 April 2009
Wockhardt’s debt hard pill to swallow for investors
01 April 2009
Fortis seeks nod for rights issue; may acquire Wockhartdt
31 March 2009
Wockhardt to launch ulcer drug Ranitidine in the US
26 February 2009
Wockhardt gets US FDA approval for paediatrics drug
04 December 2008
Wockhardt gets USFDA approval for insomnia drug sale
14 November 2008
Wockhardt gets US FDA nod to market Ceftazidime injections
16 October 2008
Lintas Bangalore bags Wockhardt account
13 October 2008
Wockhardt says derivative losses not to affect Q1 performance
24 March 2008
Wockhardt's Azithromycin to battle Pfizer's Zithromax in the US market
13 February 2008
Emaar IPO yet undersubscribed; Wockhardt withdraws issue
07 February 2008
Wockhardt Hospitals plans Rs569 crore investment in hospital projects
21 January 2008
Wockhardt to demerge R&D business
18 January 2008
Wockhardt enters billion-dollar anti-allergic Zyrtec market in the US
02 January 2008
Wockhardt acquires US pharma firm Morton Grove Pharmaceuticals
24 October 2007
Wockhardt gets US FDA nod to enter the $2.6 billion Norvasc market
17 September 2007
Internal accruals to fund Negma acquisition: Khorakiwala
03 May 2007
Wockhardt acquires France`s Negma Labs for Rs1,090 crore
03 May 2007
Wockhardt to launch Italy''s B-Lift range of dermatology products in India
23 April 2007
Wockhardt to introduce treatment for dermatological scars
17 April 2007
The bigger picture
04 April 2007
What the benefactors say
04 April 2007
Wockhardt receives US FDA approval for diuretic injection
28 March 2007
Healthcare industry demands deeper reforms
28 February 2007
Wockhardt signs in-licensing pact with Crawford Healthcare of UK
22 January 2007
Wockhardt, Dr Reddy's launch generic Ondansetron in the US
27 December 2006
FDA orders withdrawal of Wockhardt's insulin brand 'Wosulin'
25 November 2006
Wockhardt Q3 net up 14 per cent at Rs74 crore, sales up 22 per cent at Rs438 crore
26 October 2006
Wockhardt acquires Pinewood for $150 million, fourth European acquisition
03 October 2006
Wockhardt to upgrade and manage hospital in Rajkot
20 September 2006
Wockhardt to develop SEZ near Aurangabad for its global biopharma hub
18 September 2006
Wockhardt close to acquiring Pinewood: CNBC
13 September 2006
Wockhardt's Cefotaxime injection receives US FDA approval
31 August 2006
Wockhardt acquires Dumex with Protinex, Farex brands from Royal Numico NV
30 June 2006
Wockhardt UK expanding Byetta manufacturing capacity
16 June 2006
Wockhardt gets US FDA approval for anti-epilepsy drug
14 June 2006
Wockhardt in-licenses dermatology drug from LSI of UK
05 June 2006
Wockhardt receives US FDA approval for clarithromycin tablets
01 June 2006
US FDA approves Wockhardt's Waluj plant
11 May 2006
Wockhardt to raise up to $800 million to fund overseas acquisitions
16 March 2006
Huzaifa Khorakiwala Dr Murtaza Khorakiwala join Wockhardt board
16 March 2006
Wockhardt receives US FDA approval for Ranitidine OTC version
27 February 2006
Wockhardt amongst first to receive US FDA approval for Zonisamide Capsules
26 December 2005
Wockhardt becomes South Asia''s first JCI-accredited super-speciality hospital
11 November 2005
Datamatics appoints H Khorakiwala, Dr Uday Salunkhe as independent directors
27 October 2005
Wockhardt joins $billion league
20 July 2005
Wockhardt becomes only pharmaceutical Superbrand in India
20 July 2005
Wockhardt launches India''s first automatic insulin delivery device and recombinant insulin cartridge
17 February 2005
Wockhardt acquires German firm Esparma
07 May 2004
Wockhardt Hospital wins excellence in communications awards
26 March 2004
Human touch for humanity
05 September 2003
Wockhardt buys CP Pharma
10 July 2003
There is no plan to sell Vitamin B12 business, says Wockhardt
24 June 2003
Harvard Medical International, Wockhardt honour five doctors
17 February 2003
Wockhardt in talks with Watson
24 December 2001
Pharma companies in talks with MIDC
13 December 2001
Leading firms, Specialty Ranbaxy tie up
01 December 2001
Wockhardt files investigational application
15 November 2001
Drug prices revised, Wockhardt to gain
13 August 1999
Wockhardt preparing for competition
27 April 1999
Wockhardt to separate non-pharma business
23 April 1999
Wockhardt sets Rs 70-crore target for nutrition business
22 April 1999
The story so far
01 January 1900
What Wockhardt did
01 January 1900
 search domain-b
  go